LPL Financial’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-37,980
| Closed | -$66.5K | – | 5669 |
|
|
2025
Q1 | $66.5K | Sell |
37,980
-12,000
| -24% | -$15.8K | ﹤0.01% | 5116 |
|
|
2024
Q4 | $79K | Sell |
49,980
-8,000
| -14% | -$12.3K | ﹤0.01% | 5036 |
|
|
2024
Q3 | $91K | Buy |
57,980
+11,000
| +23% | +$18.2K | ﹤0.01% | 4912 |
|
|
2024
Q2 | $83.9K | Sell |
46,980
-66,500
| -59% | -$154K | ﹤0.01% | 4768 |
|
|
2024
Q1 | $327K | Buy |
+113,480
| New | +$185K | ﹤0.01% | 4133 |
|
|
2023
Q3 | – | Sell |
-18,502
| Closed | -$27.2K | – | 4777 |
|
|
2023
Q2 | $27.2K | Buy |
18,502
+5,000
| +37% | +$6.66K | ﹤0.01% | 4490 |
|
|
2023
Q1 | $11.4K | Buy |
+13,502
| New | +$17.9K | ﹤0.01% | 4447 |
|
|
2016
Q1 | – | Sell |
-195
| Closed | -$202K | – | 3188 |
|
|
2015
Q4 | $202K | Buy |
195
+98
| +101% | +$98.2K | ﹤0.01% | 2816 |
|
|
2015
Q3 | $76K | Sell |
97
-46
| -32% | -$47.2K | ﹤0.01% | 2682 |
|
|
2015
Q2 | $176K | Sell |
143
-8
| -5% | -$12.9K | ﹤0.01% | 2664 |
|
|
2015
Q1 | $316K | Sell |
151
-8
| -5% | -$17.4K | ﹤0.01% | 2204 |
|
|
2014
Q4 | $306K | Buy |
159
+8
| +5% | +$14.2K | ﹤0.01% | 2140 |
|
|
2014
Q3 | $121K | Buy |
151
+1
| +0.7% | +$846 | ﹤0.01% | 2582 |
|
|
2014
Q2 | $145K | Sell |
150
-158
| -51% | -$135K | ﹤0.01% | 2561 |
|
|
2014
Q1 | $334K | Buy |
+308
| New | +$341K | ﹤0.01% | 2062 |
|
Other funds holding RGLS
LPL Financial's RGLS Position: Q2 2025 in Review
LPL Financial sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 37,980 shares — an estimated $66.5K sold.
LPL Financial first reported a position in RGLS in Q1 2014 and held it in 15 quarters. The position peaked at $334K in Q1 2014. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- LPL Financial reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- LPL Financial sold 37,980 Regulus Therapeutics shares in Q2 2025, an estimated $66.5K.
- LPL Financial first reported a position in Regulus Therapeutics in Q1 2014 and held it in 15 quarters.
- LPL Financial's Regulus Therapeutics position peaked at $334K in Q1 2014.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on LPL Financial's 13F filing for Q2 2025, filed 12 Aug 2025.